Canine adenovirus vectors

Patent metadata

Field	Value
Publication number	US-10329586-B2
Application number	US-201715706898-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 20, 2016
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.

First claim

What is claimed is:

1. A recombinant canine adenovirus (rCAdV) vector comprising an expression cassette encoding a heterologous DNA operably linked to an equine herpesvirus-4 (EHV4) promoter sequence, wherein the EHV4 promoter sequence is either (i) an EHV4 ORF 42 promoter sequence comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO: 32, or (ii) an EHV4 ORF 70 promoter sequence comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO: 31.

2. The rCAdV vector of claim 1 , wherein the EHV4 promoter sequence is the EHV4 ORF 42 promoter sequence.

3. The rCAdV vector of claim 1 , wherein the EHV4 promoter sequence is the EHV4 ORF 70 promoter sequence.

4. The rCAdV vector of claim 2 , wherein the EHV4 ORF 42 promoter sequence comprises a polynucleotide having at least 95% sequence identity to SEQ ID NO: 30.

5. The rCAdV vector of claim 3 , wherein the EHV4 ORF 70 promoter sequence comprises a polynucleotide having at least 95% sequence identity to SEQ ID NO. 29.

6. The rCAdV vector of claim 5 , wherein the EHV4 ORF 70 promoter sequence comprises SEQ ID NO.:29.

7. The rCAdV vector of claim 4 , wherein EHV4 ORF 42 promoter sequence comprises SEQ ID NO.:30.

8. The rCAdV vector of claim 3 , wherein the EHV4 ORF 70 promoter sequence comprises SEQ ID NO.:31.

9. The rCAdV vector of claim 2 , wherein the EHV4 ORF 42 promoter sequence comprises SEQ ID NO.:32.

10. The rCAdV vector of claim 1 , wherein the rCAdV vector is an infectious canine adenovirus.

11. The rCAdV vector of claim 1 , wherein the heterologous DNA encodes an antigenic epitope, a growth factor, or, a fusion protein, or wherein the heterologous DNA comprises a therapeutic gene.

12. The rCAdV vector of claim 11 , wherein the heterologous DNA encodes the antigenic epitope.

13. The rCAdV vector of claim 12 , wherein the antigenic epitope is from a canine or feline pathogen.

14. The rCAdV vector of claim 12 , wherein the antigenic epitope is derived from a food producing animal pathogen.

15. The rCAdV vector of claim 13 , wherein the antigenic epitope is from a Morbillivirus antigen, a rabies glycoprotein, a Feline Leukemia virus (FeLV) envelope protein, an immunodeficiency virus antigen, a parvovirus antigen, or a poxvirus antigen.

16. The rCAdV vector of claim 14 , wherein the food producing animal pathogen is a swine, cattle, equine, poultry, and/or ovine pathogen.

17. An immunogenic composition comprising:
the rCAdV vector according to claim 1 ; and
a veterinary-acceptable acceptable carrier or diluent.

18. The immunogenic composition of claim 17 , wherein the carrier or diluent is suitable for oral, intradermal, intramuscular, or intranasal application.

19. A method for producing an immunogenic composition, comprising:
infecting a host cell with the rCAdV vector according to claim 1 ;
cultivating the infected host cell;
harvesting the rCAdV vector from the infected host cell; and
admixing the harvested rCAdV vector with a pharmaceutically acceptable carrier.

20. A method for inducing an immune response against a pathogen in an animal, comprising:
administering to the animal an effective amount of the immunogenic composition according to claim 17 .

21. The method of claim 20 , wherein the immunogenic composition is administered once.

22. The method of claim 20 , wherein the immunogenic composition is administered as two doses.

23. The method of claim 20 , wherein the immunogenic composition is administered orally, intradermally, intramuscular, or intranasally.

24. A kit for inducing an immune response against a pathogen in an animal, comprising:
the immunogenic composition according to claim 17 ; and
a dispenser capable of administering the immunogenic composition to the animal.

25. A eukaryotic host cell line which expresses the rCAdV vector according to claim 1 .

26. The eukaryotic host cell line of claim 25 , wherein the host cell line is a PK/WRL cell line, a RK13 cell line, a MDBK cell line, a ST cell line, an AI-ST cell line, a VERO cell line, a Sf9 cell line, a Sf21, a Sf plus cell line, or a MDCK cell line.

27. A prokaryotic host cell line which expresses the rCAdV vector according to claim 1 .

Assignees

• Boehringer Ingelheim Vetmedica Gmbh

Inventors

• Gallei Andreas
• Koukuntla Ramesh
• Mandell Robert Barry
• Mundt Alice
• REHMET Kristina
• Vaughn Eric Martin

Classifications

• A61K39/12

  Viral antigens · CPC title

• A61K39/295

  Polyvalent viral antigens (vaccinia virus or variola virus A61K39/285); Mixtures of viral and bacterial antigens · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title

• A61K39/205

  Rhabdoviridae, e.g. rabies virus · CPC title